Search Thermo Fisher Scientific
2020 Thermo Fisher Scientific
Protein Expression User Group Meeting
In this Protein Expression User Group Meeting presents:
Part I:
From Synthetic Gene to Protein Purification: Confidence with Gene Synthesis Services to Accelerate Protein Drug Development
Speaker : Dr. Jay Yang
Market Development Manager,
Synthetic Biology and Licensing and Commercial Supplies, Thermo Fisher Scientific
Part II:
Enhancing Protein Expression Efficiencies with the Expi™ Protein Expression Systems
Speaker : Dr. Roland Leathers
Senior Strategic Alliances Manager, Cell Biology,
Thermo Fisher Scientific
Learning Objectives:
- Understand how the Expi™ systems can be used to accelerate biopharmaceutical and vaccine development timelines
- Learn how to leverage GeneArt™ services to accelerate protein drug development
From Synthetic Gene to Protein Purification: Confidence with Gene Synthesis Services to Accelerate Protein Drug Development
Speaker:
Dr. Jay Yang
Market Development Manager,
Synthetic Biology and Licensing and Commercial Supplies, Thermo Fisher Scientific
Biography:
Jay received his PhD in Biochemistry from the University of Toronto in Canada in 2012, where his research work contributed to a better understanding in genome stability and DNA double-stranded break repair. He then joined Singer Instruments as a Business Development Manager, helping labs automate workflows for strain engineering and drug screening in microbial organisms. Jay serves as a Market Development Manager at Thermo Fisher Scientific since 2017, where he continues to leverage his expertise in gene synthesis and genome editing to help customers accelerate drug development and product commercialization.
Abstract:
Reliable expression of recombinant proteins in human, CHO or insect cells is essential for many aspects of biomedical research and drug development, but is often hampered by low expression yields that limit subsequent structural and functional analyses. The full portfolio of Thermo Fisher Scientific, from GeneArt™ gene synthesis to optimized eukaryotic / mammalian expression systems, offers researchers the unique opportunity to perfect their gene expression results. Our proprietary sequence optimization algorithm (Invitrogen ™ GeneArt™ GeneOptimizer™ technology) enhances the sequence through a parallel multi-parameter approach. To further maximize protein yield, you can choose from our best serum-free Gibco™ Expi™ 293, Gibco™ Expi™ CHO and Sf9 expression systems.
This holistic approach - from electronic gene sequence or accession number to the purified protein - is the most efficient way to exploit your gene-to-protein workflow for highest performance, either by purchasing reagents for internal work or outsourcing the entire workflow as a highly customized service to the GeneArt™ protein team. This procedure is ideal for rapid protein production early on during drug development and is highly advantageous to minimize changes in protein quality/function observed when moving from R&D to bioproduction. Starting with only a digital sequence, Invitrogen™ GeneArt™ Gene to Protein services offer a rapid and dependable way to obtain correctly folded native protein.
Learning Objectives:
- Understand the broad spectrum of GeneArt™ services, from gene synthesis to protein purification.
- How our proprietary GeneOptimizer™ algorithm results enhances protein expression
- Strategies for high-titer protein expression using highly advanced protein expression systems
- How your lab can leverage GeneArt™ services to accelerate early stage of drug development
Enhancing Protein Expression Efficiencies with the Expi™️ Protein Expression Systems
Speaker:
Dr. Roland Leathers
Senior Strategic Alliances Manager, Cell Biology,
Thermo Fisher Scientific
Biography:
Roland Leathers is an Englishman based in Basel, Switzerland. He finished his PhD in cell and molecular biology at the University of Sheffield University, UK in 1989. Following a post-doc in Sheffield UK, he moved to the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland to lead an academic-industrial research project in collaboration with Hoffmann La Roche. In 1993 he joined Life Technologies, now Thermo Fisher Scientific, and has since occupied numerous scientific and business positions within the organization. He is currently Senior Strategic Alliances Manager for Thermo Fisher’s Cell Biology business unit, supporting clients and research collaborations across EMEA and Asia Pacific. His scientific domains of expertise extend from protein expression, genome editing, cell line engineering and assay development for drug discovery screening.
Abstract:
Modern applications such as biopharmaceuticals and vaccine development, structural biology, membrane protein studies and assay development are imposing new demands with regard to accessing high yields of quality protein rapidly. To this end, scientists need protein expression systems that provide the highest yields of quality protein at speed, while also offering substantial cost- and workflow-efficiencies to reduce expression timelines and process costs. Ideally, the system should also provide a simplified path to scale-up as needs for protein grow.
Gibco™ Expi™ Expression Systems achieve these goals by bringing together specialized high-density cell suspension cultures, Gibco™ chemically defined media, Invitrogen™ molecular biology and Lipofectamine™ transfection technologies. This combination of defined, fully integrated and optimized system components provides an end-to-end solution for high-yield, scalable and cost-effective protein expression in mammalian (ExpiCHO™ and Expi293™) and insect (ExpiSf™) cell hosts.
Recent developments in the Expi toolbox provide further options to meet today’s more challenging applications. The availability of cGMP banked Expi293 and ExpiCHO cell lines, facilitates the expression of protein in a regulated environment, that’s then ready for use in the clinic. In structural biology applications, the availability of engineered Expi293 expression cell lines (e.g. Inducible, GNTI- and Inducible GNTI- Expi293 cell lines) allows the controlled and regulated expression of proteins carrying simplified post-translational modifications to facilitate downstream structural analysis. While the Expi293 Methionine-deficient system facilitates the metabolic labelling of proteins ready for NMR or multiwavelength anomalous dispersion (MAD) studies. Together, these new tools significantly enhance the ability of researchers to produce proteins for structural biology analysis.
Gibco™ Expi™ Expression Systems provide you with the highest yields of quality protein in the least time and with the greatest cost-efficiency!
Learning Objectives:
- Understand the differences between and the ExpiCHO™, Expi293™ and ExpiSf™ protein expression systems and their uses
- Understand how the Expi™ systems can be used to accelerate biopharmaceutical and vaccine development timelines
- Understand how the new Expi293 tools for glycan modulation, inducible expression, and protein labeling are suitable for structural biology and challenging protein applications.
- Understand how a baculovirus expression vector system can be used for expression of recombinant proteins, virus-like particles, and Adeno-associated virus.
From Synthetic Gene to Protein Purification: Confidence with Gene Synthesis Services to Accelerate Protein Drug Development
Speaker:
Dr. Jay Yang
Market Development Manager,
Synthetic Biology and Licensing and Commercial Supplies, Thermo Fisher Scientific
Biography:
Jay received his PhD in Biochemistry from the University of Toronto in Canada in 2012, where his research work contributed to a better understanding in genome stability and DNA double-stranded break repair. He then joined Singer Instruments as a Business Development Manager, helping labs automate workflows for strain engineering and drug screening in microbial organisms. Jay serves as a Market Development Manager at Thermo Fisher Scientific since 2017, where he continues to leverage his expertise in gene synthesis and genome editing to help customers accelerate drug development and product commercialization.
Abstract:
Reliable expression of recombinant proteins in human, CHO or insect cells is essential for many aspects of biomedical research and drug development, but is often hampered by low expression yields that limit subsequent structural and functional analyses. The full portfolio of Thermo Fisher Scientific, from GeneArt™ gene synthesis to optimized eukaryotic / mammalian expression systems, offers researchers the unique opportunity to perfect their gene expression results. Our proprietary sequence optimization algorithm (Invitrogen ™ GeneArt™ GeneOptimizer™ technology) enhances the sequence through a parallel multi-parameter approach. To further maximize protein yield, you can choose from our best serum-free Gibco™ Expi™ 293, Gibco™ Expi™ CHO and Sf9 expression systems.
This holistic approach - from electronic gene sequence or accession number to the purified protein - is the most efficient way to exploit your gene-to-protein workflow for highest performance, either by purchasing reagents for internal work or outsourcing the entire workflow as a highly customized service to the GeneArt™ protein team. This procedure is ideal for rapid protein production early on during drug development and is highly advantageous to minimize changes in protein quality/function observed when moving from R&D to bioproduction. Starting with only a digital sequence, Invitrogen™ GeneArt™ Gene to Protein services offer a rapid and dependable way to obtain correctly folded native protein.
Learning Objectives:
- Understand the broad spectrum of GeneArt™ services, from gene synthesis to protein purification.
- How our proprietary GeneOptimizer™ algorithm results enhances protein expression
- Strategies for high-titer protein expression using highly advanced protein expression systems
- How your lab can leverage GeneArt™ services to accelerate early stage of drug development
Enhancing Protein Expression Efficiencies with the Expi™️ Protein Expression Systems
Speaker:
Dr. Roland Leathers
Senior Strategic Alliances Manager, Cell Biology,
Thermo Fisher Scientific
Biography:
Roland Leathers is an Englishman based in Basel, Switzerland. He finished his PhD in cell and molecular biology at the University of Sheffield University, UK in 1989. Following a post-doc in Sheffield UK, he moved to the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland to lead an academic-industrial research project in collaboration with Hoffmann La Roche. In 1993 he joined Life Technologies, now Thermo Fisher Scientific, and has since occupied numerous scientific and business positions within the organization. He is currently Senior Strategic Alliances Manager for Thermo Fisher’s Cell Biology business unit, supporting clients and research collaborations across EMEA and Asia Pacific. His scientific domains of expertise extend from protein expression, genome editing, cell line engineering and assay development for drug discovery screening.
Abstract:
Modern applications such as biopharmaceuticals and vaccine development, structural biology, membrane protein studies and assay development are imposing new demands with regard to accessing high yields of quality protein rapidly. To this end, scientists need protein expression systems that provide the highest yields of quality protein at speed, while also offering substantial cost- and workflow-efficiencies to reduce expression timelines and process costs. Ideally, the system should also provide a simplified path to scale-up as needs for protein grow.
Gibco™ Expi™ Expression Systems achieve these goals by bringing together specialized high-density cell suspension cultures, Gibco™ chemically defined media, Invitrogen™ molecular biology and Lipofectamine™ transfection technologies. This combination of defined, fully integrated and optimized system components provides an end-to-end solution for high-yield, scalable and cost-effective protein expression in mammalian (ExpiCHO™ and Expi293™) and insect (ExpiSf™) cell hosts.
Recent developments in the Expi toolbox provide further options to meet today’s more challenging applications. The availability of cGMP banked Expi293 and ExpiCHO cell lines, facilitates the expression of protein in a regulated environment, that’s then ready for use in the clinic. In structural biology applications, the availability of engineered Expi293 expression cell lines (e.g. Inducible, GNTI- and Inducible GNTI- Expi293 cell lines) allows the controlled and regulated expression of proteins carrying simplified post-translational modifications to facilitate downstream structural analysis. While the Expi293 Methionine-deficient system facilitates the metabolic labelling of proteins ready for NMR or multiwavelength anomalous dispersion (MAD) studies. Together, these new tools significantly enhance the ability of researchers to produce proteins for structural biology analysis.
Gibco™ Expi™ Expression Systems provide you with the highest yields of quality protein in the least time and with the greatest cost-efficiency!
Learning Objectives:
- Understand the differences between and the ExpiCHO™, Expi293™ and ExpiSf™ protein expression systems and their uses
- Understand how the Expi™ systems can be used to accelerate biopharmaceutical and vaccine development timelines
- Understand how the new Expi293 tools for glycan modulation, inducible expression, and protein labeling are suitable for structural biology and challenging protein applications.
- Understand how a baculovirus expression vector system can be used for expression of recombinant proteins, virus-like particles, and Adeno-associated virus.